

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE quality standards

Equality impact assessment

Serious eye disorders

The impact on equality has been assessed during quality standard development according to the principles of the NICE equality policy.

1. TOPIC ENGAGEMENT STAGE

1.1 Have any potential equality issues been identified during this stage of the development process?

The incidence of serious eye disorders and sight loss is higher among older people, many of whom may not seek treatment as they feel this is an expected part of the aging process.

1.2 Have any population groups, treatments or settings been excluded from coverage by the quality standard at this stage in the process. Are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

This quality standard will not cover serious eye disorders in children and young people. These conditions are rare in children and young people and would be treated by specialist paediatric services.

Completed by lead technical analyst: Rachel Gick

Date: 04/12/2017

Approved by NICE quality assurance lead: Nick Baillie

Date: 07/12/2017

Date: 7/12/2017

1.0.7 DOC EIA

2. PRE-CONSULTATION STAGE

2.1 Have any potential equality issues been identified during the development of the quality standard (including those identified during the topic engagement process)? How have they been addressed?

None identified.

2.3 Do the draft quality statements make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

None identified.

2.4 Is there potential for the draft quality statements to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

None identified.

2.5 Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 2.1, 2.2 or 2.3, or otherwise fulfil NICE's obligation to advance equality?

None identified.

Completed by lead technical analyst Rachel Gick

Date 30 August 2018

Approved by NICE quality assurance lead Nick Baillie

Date 30 August 2018

1.0.7 DOC EIA

3. POST CONSULTATION STAGE

3.1 Have any additional potential equality issues been raised during the consultation stage, and, if so, how has the committee addressed them?

The importance of providing information in accessible formats relating to CVI registration (statement 6) was highlighted by stakeholders. The committee agreed that this could be referred to in an equality and diversity section for this statement. This section cites NHS England's Accessible Information Standard and the need for communication to be adapted to involve adults with decisions relating to the certification of vision impairment process.

3.2 If the quality statements have changed after the consultation stage, are there any that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3.3 If the quality statements have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

3.4 If the quality statements have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 3.1, 3.2 and 3.3, or otherwise fulfil NICE's obligations to advance equality?

No.

1.0.7 DOC EIA

Completed by lead technical analyst Rachel Gick

Date 16 January 2019

Approved by NICE quality assurance lead Nick Baillie 16
January 2019

1.0.7 DOC EIA

4. After Guidance Executive amendments – if applicable

4.1 Outline amendments agreed by Guidance Executive below, if applicable:

N/A

Completed by lead technical analyst Rachel Gick

Date 24 January 2019

Approved by NICE quality assurance lead Nick Baillie

Date 24 January 2019

© NICE 2019 All rights reserved. Subject to [Notice of rights](#).